Pemigatinib treatment for intrahepatic cholangiocarcinoma with <scp>FGFR2</scp> fusion detected by a liquid comprehensive genomic profiling test-Reference-Cited by-同舟云学术

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

Published:2023-07 Issue:7 Volume:11 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Ishido Shun¹^ORCID,Tamaki Nobuharu¹,Inada Kento¹,Itakura Jun¹,Takahashi Yuka¹,Uchihara Naoki¹,Suzuki Keito¹,Tanaka Yuki¹,Miyamoto Haruka¹,Yamada Michiko¹,Matsumoto Hiroaki¹,Nobusawa Tsubasa¹,Keitoku Taisei¹,Takaura Kenta¹,Tanaka Shohei¹,Maeyashiki Chiaki¹,Yasui Yutaka¹,Tsuchiya Kaoru¹,Nakanishi Hiroyuki¹,Kurosaki Masayuki¹,Izumi Namiki¹

Affiliation:

1. Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan

Abstract

Key Clinical MessageThe liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.7664

Reference21 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease

3. Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality

4. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology

5. Systemic therapies for intrahepatic cholangiocarcinoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful intrahepatic cholangiocarcinoma conversion surgery after administration of fibroblast growth factor receptor inhibitor;Clinical Journal of Gastroenterology;2024-07-10

2. Multiple drugs;Reactions Weekly;2023-10-28